Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pluri Inc. (PLUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: PLUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.05% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.46M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.69 | 52 Weeks Range 3.33 - 7.13 | Updated Date 09/12/2025 |
52 Weeks Range 3.33 - 7.13 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1264.64% |
Management Effectiveness
Return on Assets (TTM) -36.57% | Return on Equity (TTM) -1833.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45371711 | Price to Sales(TTM) 39.13 |
Enterprise Value 45371711 | Price to Sales(TTM) 39.13 | ||
Enterprise Value to Revenue 43.88 | Enterprise Value to EBITDA -1.28 | Shares Outstanding 7871150 | Shares Floating 3861237 |
Shares Outstanding 7871150 | Shares Floating 3861237 | ||
Percent Insiders 43.41 | Percent Institutions 19.65 |
Upturn AI SWOT
Pluri Inc.
Company Overview
History and Background
Pluri Inc., formerly known as Pluristem Therapeutics, was founded in 2001. It's a biotechnology company focused on cell-based regenerative medicine platforms and placental-derived cell therapy products.
Core Business Areas
- Placental-Derived Cell Therapy: Development and manufacturing of cell therapy products derived from human placenta for various indications, including acute radiation syndrome and muscle injury.
- Regenerative Medicine: Research and development of cell-based therapies aimed at regenerating damaged tissues and organs.
Leadership and Structure
The company has a board of directors and an executive management team leading the organization. Details fluctuate; consult Pluri's investor relations for the most up-to-date information.
Top Products and Market Share
Key Offerings
- PLX-R18: Cell therapy product for the treatment of acute radiation syndrome (ARS). Market share is difficult to precisely quantify due to the emerging nature of the market. Competitors include companies developing other approaches for ARS, such as cytokine inhibitors.
- PLX-PAD: Cell therapy product for the treatment of muscle injury following hip fracture. Market share information is not publicly available. Competitors involve other regenerative medicine companies.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, driven by advances in cell therapy, gene therapy, and tissue engineering. It faces regulatory hurdles and high development costs.
Positioning
Pluri Inc. is positioned as a leader in placental-derived cell therapy. Its competitive advantage lies in its proprietary technology and manufacturing capabilities.
Total Addressable Market (TAM)
The TAM for regenerative medicine is estimated to be in the tens of billions of dollars and expected to grow. Pluri Inc. is targeting specific indications within this broader market.
Upturn SWOT Analysis
Strengths
- Proprietary placental cell technology
- Advanced manufacturing capabilities
- Potential for breakthrough therapies
- Experienced management team
Weaknesses
- Limited commercialized products
- High R&D expenses
- Reliance on clinical trial success
- History of net losses
Opportunities
- Expanding into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Government funding and support
Threats
- Regulatory hurdles
- Competition from other regenerative medicine companies
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- MESO
- BMY
- CRSP
Competitive Landscape
Pluri Inc. faces competition from larger, more established companies in the biotechnology and pharmaceutical industries. Its strengths lie in its placental cell technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development progress and clinical trial advancements.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for PLX-R18 and PLX-PAD, seeking partnerships, and expanding manufacturing capacity.
Summary
Pluri Inc. is a biotechnology company with a focus on regenerative medicine. Its placental-derived cell therapy platform holds promise but faces high R&D expenses and regulatory hurdles. Clinical trial successes and strategic partnerships are critical for future growth. The company needs to demonstrate efficacy and secure funding for continued development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Financial News Outlets
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pluri Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-06-30 | President, CEO & Director Mr. Yaacov Yanay | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.pluri-biotech.com |
Full time employees 106 | Website https://www.pluri-biotech.com | ||
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.